Sodium Acetate C11

Phase 2Small molecule

PPhoenix Molecular Imaging

Sodium Acetate C11 is one of 50 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Brain GliomaActive, not recruiting

Prostate CarcinomaPhase 2

Active, not recruiting

Brain GliomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Prostate Carcinoma

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

2 2

Nubeqa

Bayer

Approved

1 3

Farxiga

Ritalin

Xtandi

Estrace

Balversa

Lynparza

Zometa

Plaquenil

Alnylam Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Glioma1 trial

C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression

Withdrawn·PPhoenix Molecular Imaging·Phase 2/3·NCT01961934

Prostate Carcinoma1 trial

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Completed·PPhoenix Molecular Imaging·Phase 2·NCT01304485·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sodium Acetate C11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Acetate C11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Acetate C11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phoenix Molecular Imaging company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhoenix Molecular Imaging

Sodium Acetate C11

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Glioma1 trial

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News